Cargando…
The cost and value of cancer drugs – are new innovations outpacing our ability to pay?
Cancer drug expenditures have been increasing significantly in countries around the world. A recent paper in the IJHPR provides new knowledge and insights into this global phenomenon by analyzing how it is playing out in an Israeli health plan with over two million members, whose state-of-the-art in...
Autores principales: | Goldstein, Daniel A., Stemmer, Salomon M., Gordon, Noa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032240/ https://www.ncbi.nlm.nih.gov/pubmed/27688873 http://dx.doi.org/10.1186/s13584-016-0097-0 |
Ejemplares similares
-
Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System
por: Gordon, Noa, et al.
Publicado: (2021) -
Scientists are sprinting to outpace the novel coronavirus
por: Ghebreyesus, Tedros Adhanom, et al.
Publicado: (2020) -
Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
por: Carlson, Josh, et al.
Publicado: (2009) -
When innovation outpaces regulations: The legal challenges for direct‐to‐patient supply of investigational medicinal products
por: Malone, Maeve, et al.
Publicado: (2021) -
Nutrients cause grassland biomass to outpace herbivory
por: Borer, E. T., et al.
Publicado: (2020)